A Phase 3 interventional study of Belatacept and Tacrolimus in Kidney Transplantation, sponsored by Bristol-Myers Squibb. Completed at 117 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-05.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-60 months after kidney transplant.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Belatacept 5 mg/kg intravenous 30 minute infusion on Days 1, 15, 29, 43, 57 then every 28 days for 24 months
Drug: Belatacept
Tacrolimus 4-11 ng/mL tablet orally according to package insert for 24 months Cyclosporine 50-250 ng/mL tablet orally according to package insert for 24 months
Drug: Tacrolimus · Drug: Cyclosporine
Also known as: BMS 224818, Nulojix®
Percentage of Participants Who Survive With a Functional Graft at 24 Months
Percentage of participants who survive with a functional graft at 24 months post-randomization
Time frame: at 24 Months
Percentage of Participants Who Survive With a Functional Graft at 12 Months
Percentage of participants who survive with a functional graft at 12 months post-randomization
Time frame: at 12 Months
Number of Participants With a Biopsy Proven Acute Rejection (BPAR)
The number of clinically suspected, biopsy proven acute rejection (AR) at 12 and 24 months post-randomization includes participants with at least one cellular and/or humoral BPAR event.
Time frame: at 12 and 24 Months
Number of Participants With Varying Severity of BPAR
Number of participants in each severity of clinically suspected, biopsy proven acute rejection (AR) at 12 and 24 months post-randomization
Time frame: at 12 and 24 months
Mean Change From Baseline of Calculated Glomerular Filtration Rate (cGFR) - Percent Change
Mean change from baseline cGFR as calculated by the 4-variable MDRD equation to 12 and 24 months post-randomization - Percent Change
Time frame: at 12 and 24 months
Mean Change From Baseline of Calculated Glomerular Filtration Rate (cGFR) - Adjusted Change
Mean change from baseline cGFR as calculated by the 4-variable MDRD equation to 12 and 24 months post-randomization - Adjusted Change
Time frame: at 12 and 24 months
Mean Calculated Glomerular Filtration Rate (cGFR)
Mean cGFR by study visit, as calculated by the 4-variable MDRD equation.
Time frame: up to 24 months
Slope Analysis of cGFR
Slopes of cGFR as plotted from baseline as well as from Month 3, to Month 12 and Month 24 post-randomization
Time frame: at 12 and 24 Months
Slope Analysis of 1/Serum Creatinine
Slopes of 1/serum creatinine as plotted from baseline as well as from Month 3, to Month 12 and Month 24 post-randomization
Time frame: at 12 and 24 Months
Percentage of Participants With > 5% and >10% Improvement Over Baseline cGFR
Percentage of participants with \> 5% and \>10% improvement over baseline cGFR, at 12 and 24 months post-randomization
Time frame: at 12 and 24 Months
Mean Urine Protein/ Creatinine Ratio (UPCR)
Urine protein/ creatinine ratio (UPCR) at baseline, 3, 6, 12 and 24 months post randomization
Time frame: Up to 24 Months
Mean Change From Baseline in Systolic and Diastolic Blood Pressure
Mean change in systolic and diastolic blood pressure from baseline to 12 and 24 months post randomization
Time frame: at 12 and 24 months
Number of Antihypertensive Medications Used to Control Hypertension
The total number of antihypertensive medications used to control hypertension
Time frame: at baseline, 12 and 24 Months
Number of Participants With Donor Specific Antibodies (DSA)
Number of participants with donor specific antibodies (DSA) at Baseline/Day 1, and Months 12 and 24 post-randomization
Time frame: at baseline, 12 and 24 months
Mean Number of Symptom Occurrence and Symptom Distress
The frequency of symptom occurrence and symptom distress as measured with the Modified Transplant Symptom Occurrence and Symptom Distress Scale-59R (MTSOSD-59R) at baseline, Week 6, and Months 3, 6, and 12 post-randomization. Higher scores in the MTSOSD-59R indicate a greater symptom and symptom distress burden than lower scores.
Time frame: up to 12 Months
Number of Participants With an Adverse Event of Special Interest
Number of participants with an adverse event of special interests. Adverse events of special interest include: Serious Infections, Post-Transplant Lymphoproliferative Disorder (PTLD), Progressive multifocal leukoencephalopathy (PML), Malignancies (other than PTLD) including non-melanoma skin carcinomas, Tuberculosis Infections, CNS infections, Viral Infections and Infusion related reactions.
Time frame: 24 Months
Number of Participants With Marked Laboratory Abnormalities
Number of participants with Marked Laboratory Abnormalities
Time frame: 24 Months
Mean Change From Baseline in Vital Signs: Heart Rate
The mean change from baseline in measured heart rate
Time frame: at 12 and 24 months
| Milestone | Belatacept | CNI-Based Regimen |
|---|---|---|
| Started | 223 | 223 |
| Completed | 221 | 222 |
| Not completed | 2 | 1 |
| Withdrew: Not treated | 2 | 1 |
| Milestone | Belatacept | CNI-Based Regimen |
|---|---|---|
| Started | 221 | 222 |
| Completed | 195 | 186 |
| Not completed | 26 | 36 |
| Withdrew: Adverse event | 12 | 7 |
| Withdrew: Death | 3 | 3 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Poor/non compliance | 0 | 3 |
| Withdrew: Request to discontinue | 6 | 11 |
| Withdrew: No longer meets study criteria | 3 | 10 |
| Withdrew: Withdrew consent | 1 | 2 |
Percentage of participants who survive with a functional graft at 24 months post-randomization
| Percentage | Belatacept | CNI-Based Regimen |
|---|---|---|
| Percentage of Participants Who Survive With a Functional Graft at 24 Months | 98.2 (95.5 to 99.5) | 97.3 (95.2 to 99.4) |
Percentage of participants who survive with a functional graft at 12 months post-randomization
| Percentage | Belatacept | CNI-Based Regimen |
|---|---|---|
| Percentage of Participants Who Survive With a Functional Graft at 12 Months | 98.7 (96.1 to 99.7) | 99.1 (96.8 to 99.9) |
The number of clinically suspected, biopsy proven acute rejection (AR) at 12 and 24 months post-randomization includes participants with at least one cellular and/or humoral BPAR event.
| Participants | Belatacept | CNI-Based Regimen |
|---|---|---|
| at 12 Months | 18 | 4 |
| at 24 Months | 18 | 9 |
Number of participants in each severity of clinically suspected, biopsy proven acute rejection (AR) at 12 and 24 months post-randomization
| Participants | Belatacept | CNI-Based Regimen |
|---|---|---|
| at 12 Months — Mild Acute (IA) | 2 | 2 |
| at 12 Months — Mild Acute (IB)1 | 1 | 0 |
| at 12 Months — Moderate Acute (IIA) | 7 | 0 |
| at 12 Months — Moderate Acute (IIB) | 6 | 0 |
| at 12 Months — Severe Acute (III) | 4 | 1 |
| at 24 Months — Mild Acute (IA) | 2 | 4 |
| at 24 Months — Mild Acute (IB)1 | 1 | 0 |
| at 24 Months — Moderate Acute (IIA) | 7 | 1 |
| at 24 Months — Moderate Acute (IIB) | 6 | 0 |
| at 24 Months — Severe Acute (III) | 4 | 1 |
Mean change from baseline cGFR as calculated by the 4-variable MDRD equation to 12 and 24 months post-randomization - Percent Change
| Percent Change | Belatacept | CNI-Based Regimen |
|---|---|---|
| at 12 Months | 13.2 (10.4 to 16.0) | -0.3 (-2.9 to 2.4) |
| at 24 Months | 15.2 (11.9 to 18.6) | 0.3 (-2.9 to 3.4) |
Mean change from baseline cGFR as calculated by the 4-variable MDRD equation to 12 and 24 months post-randomization - Adjusted Change
| mL/min/1.73m² | Belatacept | CNI-Based Regimen |
|---|---|---|
| at 12 Months | 5.6 (4.3 to 6.9) | -0.7 (-2.0 to 0.6) |
| at 24 Months | 6.2 (4.7 to 7.7) | -1.0 (-2.6 to 0.5) |
Mean cGFR by study visit, as calculated by the 4-variable MDRD equation.
| mL/min/1.73m² | Belatacept | CNI-Based Regimen |
|---|---|---|
| Screening | 49.8 (48.2 to 51.5) | 49.7 (48.2 to 51.2) |
| Baseline | 49.6 (48.0 to 51.2) | 50.7 (49.2 to 52.2) |
| Month 3 | 53.0 (51.1 to 54.9) | 50.2 (48.3 to 52.0) |
| Month 6 | 53.3 (51.3 to 55.3) | 50.9 (49.1 to 52.7) |
| Month 9 | 53.7 (51.8 to 55.6) | 50.7 (48.9 to 52.5) |
| Month 12 | 55.5 (53.4 to 57.6) | 50.5 (48.7 to 52.4) |
| Month 18 | 56.5 (54.5 to 58.5) | 51.3 (49.2 to 53.4) |
| Month 24 | 55.7 (53.7 to 57.7) | 51.1 (49.0 to 53.2) |
Slopes of cGFR as plotted from baseline as well as from Month 3, to Month 12 and Month 24 post-randomization
| mL/min/1.73m²/month | Belatacept | CNI-Based Regimen |
|---|---|---|
| Baseline to 12 Months | 0.241 (0.103 to 0.378) | 0.004 (-0.137 to 0.145) |
| Month 3 to Month 12 | 0.281 (0.072 to 0.490) | -0.159 (-0.372 to 0.055) |
| Baseline to Month 24 | 0.685 (0.426 to 0.945) | -0.112 (-0.379 to 0.155) |
| Month 3 to Month 24 | 0.658 (0.332 to 0.984) | -0.277 (-0.614 to 0.060) |
Slopes of 1/serum creatinine as plotted from baseline as well as from Month 3, to Month 12 and Month 24 post-randomization
| mg/dL/month | Belatacept | CNI-Based Regimen |
|---|---|---|
| Baseline to 12 Months | 0.034 (0.016 to 0.051) | -0.003 (-0.020 to 0.015) |
| Month 3 to Month 12 | 0.033 (0.007 to 0.059) | -0.021 (-0.048 to 0.006) |
| Baseline to Month 24 | 0.00868 (0.00537 to 0.01199) | -0.00203 (-0.00544 to 0.00138) |
| Month 3 to Month 24 | 0.00814 (0.00412 to 0.01217) | -0.00425 (-0.00842 to -0.00009) |
Percentage of participants with \> 5% and \>10% improvement over baseline cGFR, at 12 and 24 months post-randomization
| Percentage | Belatacept | CNI-Based Regimen |
|---|---|---|
| >5% improvement at 12 months | 53.4 | 28.7 |
| >10% improvement at 12 months | 43.9 | 21.5 |
| >5% improvement at 24 months | 54.3 | 29.6 |
| >10% improvement at 24 months | 48.4 | 22.0 |
Urine protein/ creatinine ratio (UPCR) at baseline, 3, 6, 12 and 24 months post randomization
| mg/mmol | Belatacept | CNI-Based Regimen |
|---|---|---|
| at Baseline | 17.80 (16.03 to 19.58) | 18.61 (15.08 to 22.14) |
| at 3 months | 22.87 (19.88 to 25.86) | 20.61 (15.50 to 25.73) |
| at 6 months | 23.42 (19.71 to 27.12) | 20.85 (15.36 to 26.35) |
| at 12 months | 29.11 (21.86 to 36.35) | 21.67 (17.70 to 25.65) |
| at 24 months | 28.81 (23.71 to 33.91) | 24.56 (19.01 to 30.10) |
Mean change in systolic and diastolic blood pressure from baseline to 12 and 24 months post randomization
| mmHg | Belatacept | CNI-Based Regimen |
|---|---|---|
| Diastolic BP at 12 Months | -1.5 (-2.9 to 0.0) | -0.6 (-2.1 to 1.0) |
| Diastolic BP at 24 Months | -1.7 (-3.3 to 0.0) | 0.5 (-1.3 to 2.3) |
| Systolic BP at 12 Months | -1.6 (-4.0 to 0.9) | 0.1 (-2.5 to 2.8) |
| Systolic BP at 24 Months | -1.3 (-4.1 to 1.6) | 1.2 (-1.7 to 4.1) |
The total number of antihypertensive medications used to control hypertension
| Number of medications | Belatacept | CNI-Based Regimen |
|---|---|---|
| at Baseline | 2.1 (1 to 5) | 2.2 (1 to 6) |
| at 12 Months | 2.3 (1 to 7) | 2.2 (1 to 6) |
| at 24 Months | 2.3 (1 to 8) | 2.3 (1 to 7) |
Number of participants with donor specific antibodies (DSA) at Baseline/Day 1, and Months 12 and 24 post-randomization
| Participants | Belatacept | CNI-Based Regimen |
|---|---|---|
| Pre Existing at baseline | 10 | 26 |
| De Novo at 12 Months | 2 | 9 |
| De Novo at 24 Months | 2 | 14 |
The frequency of symptom occurrence and symptom distress as measured with the Modified Transplant Symptom Occurrence and Symptom Distress Scale-59R (MTSOSD-59R) at baseline, Week 6, and Months 3, 6, and 12 post-randomization. Higher scores in the MTSOSD-59R indicate a greater symptom and symptom distress burden than lower scores.
| Scores on a scale | Belatacept | CNI-Based Regimen |
|---|---|---|
| Baseline symptom occurrence | 87.8 ± 20.06 | 90.7 ± 21.04 |
| Baseline symptom distress | 28.7 ± 27.07 | 34.8 ± 28.30 |
| week 6 symptom occurrence | 79.0 ± 16.52 | 88.6 ± 21.36 |
| week 6 symptom distress | 19.8 ± 21.41 | 32.4 ± 29.55 |
| Month 3 symptom occurrence | 80.5 ± 16.74 | 89.9 ± 23.45 |
| Month 3 symptom distress | 21.4 ± 23.08 | 35.2 ± 32.04 |
| month 6 symptom occurrence | 80.5 ± 17.50 | 91.8 ± 23.72 |
| month 6 symptom distress | 22.4 ± 22.18 | 36.3 ± 31.39 |
| month 12 symptom occurrence | 82.3 ± 20.08 | 91.0 ± 22.33 |
| month 12 symptom distress | 25.8 ± 25.32 | 34.4 ± 30.82 |
Number of participants with an adverse event of special interests. Adverse events of special interest include: Serious Infections, Post-Transplant Lymphoproliferative Disorder (PTLD), Progressive multifocal leukoencephalopathy (PML), Malignancies (other than PTLD) including non-melanoma skin carcinomas, Tuberculosis Infections, CNS infections, Viral Infections and Infusion related reactions.
| participants | Belatacept | CNI-Based Regimen |
|---|---|---|
| Serious Infections | 37 | 44 |
| PTLD | 1 | 0 |
| PML | 0 | 0 |
| Malignancies | 17 | 12 |
| Tuberculosis infections | 0 | 0 |
| CNS Infections | 0 | 0 |
| Viral Infections | 5 | 9 |
| Infusion Related Reactions | 13 | 0 |
Number of participants with Marked Laboratory Abnormalities
| Participants | Belatacept | CNI-Based Regimen |
|---|---|---|
| Hemoglobin (Abnormal Low) | 0 | 0 |
| Hemoglobin (Abnormal high) | 0 | 0 |
| Platelet count (Abnormal low) | 0 | 1 |
| Leukocytes (Abnormal low) | 0 | 0 |
| Lymphocytes (Abnormal low) | 29 | 10 |
| Lymphocytes (Abnormal high) | 0 | 0 |
| Neutrophils Absolute (Abnormal low) | 5 | 3 |
| Alanine Aminotransferase (Abnormal High) | 0 | 0 |
| Alkaline Phosphatase (Abnormal High) | 0 | 0 |
| Aspartate Aminotransferase (Abnormal High) | 0 | 1 |
| Total Bilirubin (Abnormal High) | 0 | 0 |
| Creatine (Abnormal High) | 5 | 4 |
| Protein/Creatinine Ratio (Abnormal High) | 0 | 0 |
| Bicarbonate (Abnormal High) | 0 | 1 |
| Total Calcium (Abnormal low) | 0 | 3 |
| Total Calcium (Abnormal high) | 1 | 2 |
| Magnesium (Abnormal low) | 0 | 0 |
| Magnesium (Abnormal high) | 0 | 0 |
| Phosphorus (Abnormal Low) | 14 | 12 |
| Potassium (Abnormal low) | 3 | 2 |
| Potassium (Abnormal high) | 1 | 5 |
| Sodium (Abnormal low) | 4 | 9 |
| Sodium (Abnormal high) | 0 | 1 |
| Albumin (Abnormal low) | 0 | 0 |
| Total Cholesterol (Abnormal High) | 13 | 17 |
| Serum Glucose (Abnormal low) | 0 | 0 |
| Serum Glucose (Abnormal high) | 18 | 18 |
| Triglycerides (Abnormal high) | 2 | 2 |
| Uric Acid (Abnormal high) | 15 | 30 |
The mean change from baseline in measured heart rate
| beats per minute (bpm) | Belatacept | CNI-Based Regimen |
|---|---|---|
| Change from baseline at 12 months | -1.8 (-3.3 to -0.2) | -0.6 (-2.2 to 1.0) |
| Change from baseline at 24 months | -1.9 (-3.5 to -0.3) | 1.0 (-0.8 to 2.8) |
Collected over 116 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Belatacept | 4/221 (1.8%) | 107/221 (48.4%) | 174/221 (78.7%) |
| CNI-Based Regimen | 5/222 (2.3%) | 95/222 (42.8%) | 168/222 (75.7%) |
| Event | Belatacept | CNI-Based Regimen |
|---|---|---|
| Kidney transplant rejectionImmune system disorders | 19/221 | 7/222 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 11/221 | 5/222 |
| Urinary tract infectionInfections and infestations | 7/221 | 7/222 |
| PneumoniaInfections and infestations | 5/221 | 7/222 |
| UrosepsisInfections and infestations | 6/221 | 3/222 |
| DiarrhoeaGastrointestinal disorders | 1/221 | 6/222 |
| GastroenteritisInfections and infestations | 1/221 | 6/222 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/221 | 5/222 |
| Acute kidney injuryRenal and urinary disorders | 4/221 | 5/222 |
| SepsisInfections and infestations | 4/221 | 2/222 |
| Event | Belatacept | CNI-Based Regimen |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 47/221 | 61/222 |
| NasopharyngitisInfections and infestations | 44/221 | 50/222 |
| Urinary tract infectionInfections and infestations | 37/221 | 33/222 |
| Oedema peripheralGeneral disorders | 22/221 | 35/222 |
| CoughRespiratory, thoracic and mediastinal disorders | 31/221 | 20/222 |
| HypertensionVascular disorders | 29/221 | 21/222 |
| HeadacheNervous system disorders | 27/221 | 23/222 |
| BronchitisInfections and infestations | 23/221 | 18/222 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 21/221 | 23/222 |
| FatigueGeneral disorders | 22/221 | 15/222 |
| Age, Continuous(Years) | Belatacept | CNI-Based Regimen | Total |
|---|---|---|---|
| Median | 55.0 ± 11.3 | 54.0 ± 11.7 | 54.0 ± 11.5 |
| Sex: Female, Male(Participants) | Belatacept | CNI-Based Regimen | Total |
|---|---|---|---|
| Female | 73 | 72 | 145 |
| Male | 150 | 151 | 301 |
| Ethnicity (NIH/OMB)(Participants) | Belatacept | CNI-Based Regimen | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 15 | 24 |
| Not Hispanic or Latino | 82 | 79 | 161 |
| Unknown or Not Reported | 132 | 129 | 261 |
| Race (NIH/OMB)(Participants) | Belatacept | CNI-Based Regimen | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 3 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 24 | 24 | 48 |
| White | 191 | 187 | 378 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 7 | 9 | 16 |
Showing the first 100 of 117 sites across 10 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2013 to primary completion in Oct 2019, 78 months.
Results were first posted in Jan 2021, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept